CHEMICALLY INDUCED TUMORS–THEIR RELATIONSHIP TO HUMAN CANCER

Author(s):  
W.H. Butler
2020 ◽  
Author(s):  
Lungwani Muungo

Tumor hypoxia and hypoxia-inducible factor 1 (HIF-1) activationare associated with cancer progression. Here, we demonstrate thatthe transcription factor TAp73 opposes HIF-1 activity through anontranscriptional mechanism, thus affecting tumor angiogenesis.TAp73-deficient mice have an increased incidence of spontaneousand chemically induced tumors that also display enhanced vascularization.Mechanistically, TAp73 interacts with the regulatory subunit(α) of HIF-1 and recruits mouse double minute 2 homolog intothe protein complex, thus promoting HIF-1α polyubiquitination andconsequent proteasomal degradation in an oxygen-independentmanner. In human lung cancer datasets, TAp73 strongly predictsgood patient prognosis, and its expression is associated with lowHIF-1 activation and angiogenesis. Our findings, supported by invivo and clinical evidence, demonstrate a mechanism for oxygenindependentHIF-1 regulation, which has important implicationsfor individualizing therapies in patients with cancer.


1978 ◽  
Vol 57 (4) ◽  
pp. 625-630 ◽  
Author(s):  
Martin Marshack ◽  
Patrick Toto ◽  
Ronald Kerman

Immune stimulation with an agent such as dinitrochlorobenzene (DNCB) may delay chemcal carcinogenesis. Dimethylbenzanthracene (DMBA) was used to chemically induce tumors in the hamster buccal pouch. Hamsters were studied for the effect of DNCB sensitization in the buccal pouch prior to or after DMBA tumor induction. At appropriate time intervals the hamsters were sacrificed and each cheek pouch was examined histologically for the development of DMBA-induced tumors and for the presence of lymphoid cells infiltrating the tumor site. The results show that DNCB immunotherapy or immunoprophylaxis prior to or following DMBA tumor induction can alter the type of tumor produced and stimulate an infiltration of lymphoid cells into the tumor area probably invoking immune defense mechanisms.


2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Marc A. Beal ◽  
Matthew J. Meier ◽  
Danielle P. LeBlanc ◽  
Clotilde Maurice ◽  
Jason M. O’Brien ◽  
...  

AbstractTransgenic rodent (TGR) models use bacterial reporter genes to quantify in vivo mutagenesis. Pairing TGR assays with next-generation sequencing (NGS) enables comprehensive mutation pattern analysis to inform mutational mechanisms. We used this approach to identify 2751 independent lacZ mutations in the bone marrow of MutaMouse animals exposed to four chemical mutagens: benzo[a]pyrene, N-ethyl-N-nitrosourea, procarbazine, and triethylenemelamine. We also collected published data for 706 lacZ mutations from eight additional environmental mutagens. We report that lacZ gene sequencing generates chemical-specific mutation signatures observed in human cancers with established environmental causes. For example, the mutation signature of benzo[a]pyrene, a carcinogen present in tobacco smoke, matched the signature associated with tobacco-induced lung cancers. Our results suggest that the analysis of chemically induced mutations in the lacZ gene shortly after exposure provides an effective approach to characterize human-relevant mechanisms of carcinogenesis and propose novel environmental causes of mutation signatures observed in human cancers.


2019 ◽  
Vol 8 (2) ◽  
pp. 192-202 ◽  
Author(s):  
Karin Schreiber ◽  
Theodore G. Karrison ◽  
Steven P. Wolf ◽  
Kazuma Kiyotani ◽  
Madeline Steiner ◽  
...  

1984 ◽  
Vol 12 (4) ◽  
pp. 344-349
Author(s):  
Pavel Kraus ◽  
Rolf Schulte-Hermann ◽  
Irene Timmermann-Trosiener ◽  
Jöurg Schuppler

2011 ◽  
Vol 29 (16) ◽  
pp. 2273-2281 ◽  
Author(s):  
Katerina Politi ◽  
William Pao

Genetically engineered mouse models (GEMMs) of human cancer were first created nearly 30 years ago. These early transgenic models demonstrated that mouse cells could be transformed in vivo by expression of an oncogene. A new field emerged, dedicated to generating and using mouse models of human cancer to address a wide variety of questions in cancer biology. The aim of this review is to highlight the contributions of mouse models to the diagnosis and treatment of human cancers. Because of the breadth of the topic, we have selected representative examples of how GEMMs are clinically relevant rather than provided an exhaustive list of experiments. Today, as detailed here, sophisticated mouse models are being created to study many aspects of cancer biology, including but not limited to mechanisms of sensitivity and resistance to drug treatment, oncogene cooperation, early detection, and metastasis. Alternatives to GEMMs, such as chemically induced or spontaneous tumor models, are not discussed in this review.


2005 ◽  
Vol 45 (1) ◽  
pp. 17-35 ◽  
Author(s):  
Jon C. Mirsalis ◽  
Julie A. Shimon ◽  
Alphonso Johnson ◽  
David Fairchild ◽  
Nathan Kanazawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document